within Pharmacolibrary.Drugs.ATC.N;

model N04BC04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 5.599999999999999e-05,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0075,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.014,
    Tlag           = 9.6
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N04BC04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ropinirole is a non-ergoline dopamine agonist primarily used in the treatment of Parkinson's disease and restless legs syndrome. It is approved for clinical use in many countries, including the USA and Europe, for both indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult male and female volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Kaye, CM, &amp; Nicholls, B (2000). Clinical pharmacokinetics of ropinirole. <i>Clinical pharmacokinetics</i> 39(4) 243–254. DOI:<a href=\"https://doi.org/10.2165/00003088-200039040-00001\">10.2165/00003088-200039040-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11069211/\">https://pubmed.ncbi.nlm.nih.gov/11069211</a></p></li><li><p>Hattori, N, et al., &amp; Sakamoto, T (2012). Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson&#x27;s disease. <i>Journal of clinical pharmacy and therapeutics</i> 37(5) 571–577. DOI:<a href=\"https://doi.org/10.1111/j.1365-2710.2012.01336.x\">10.1111/j.1365-2710.2012.01336.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22390368/\">https://pubmed.ncbi.nlm.nih.gov/22390368</a></p></li><li><p>Adamiak-Giera, U, et al., &amp; Gawrońska-Szklarz, B (2021). Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications. <i>Pharmaceutics</i> 13(9) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics13091395\">10.3390/pharmaceutics13091395</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34575471/\">https://pubmed.ncbi.nlm.nih.gov/34575471</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N04BC04;
